Ionis partner Biogen presents Phase 2 CELIA data for diranersen
The data showed robust tau reduction and meaningful clinical outcomes across doses, with the 60 mg dose achieving up to 50% slowing on MMSE.
Stay informed with the latest news and media coverage for the biggest companies in Biotechnology & Medical Research. We track all announcements, press releases, and industry mentions in real time, all in one place. Looking for another sector? Browse our industry database.
Last updated
The data showed robust tau reduction and meaningful clinical outcomes across doses, with the 60 mg dose achieving up to 50% slowing on MMSE.
The filing provides details on MSB unquoted securities and includes a PDF attachment.
The form reports a change in director's interests, filed with the ASX on July 14, 2026.
The patent covers methods for treating cancer using efti with PD-1 pathway inhibitors, expanding IP protection until 2036.
Unlock all announcements with a free trial
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced extended data from patients...
The EGFR inhibitor for exon 20-mutated non-small cell lung cancer was developed by Shanghai-based Dizal and approved by the FDA last year.
DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.
Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial SettingTOKYO and CAMBRIDGE, Mass., July 14...
Unlock all articles with a free trial
Track Every Market Move
Follow your target companies and get daily news updates delivered straight to your inbox
Start for freeBrowse the top companies in Biotechnology & Medical Research and stay on top of their latest developments.